Teleflex Incorporated Dossier
|
SectorHealth Care IndustryMedical Instruments & Supplies Beta (adjusted)0.88 Intrinsic Value $201.77median of 3 methodsbased on filings through 30 Jun 2026 Market Price $125.04Price as of 30 Sep 2026 Significantly undervaluedIntrinsic value is 61% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+61%) Data confidence Sign in to view data confidence Market Cap $5.3B Enterprise Value $7.8B Shares Outstanding 43.6M diluted Moat Rating None Next Earnings Date29 Oct 2026 Last ex-dividend14 Aug 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Teleflex is undergoing a major strategic transformation under newly appointed CEO Jason Weidman (effective June 8, 2026). The company is divesting its Acute Care, Interventional Urology, and OEM businesses for $2.03 billion to focus on core high-margin interventional, critical care, and high-acuity hospital markets. While the planned $1 billion share buyback and $800 million debt paydown provide a clear catalyst for EPS expansion in 2027, near-term performance remains messy. Q1 2026 results showed strong top-line growth driven by acquisitions, but margins were heavily pressured by tariffs, logistics costs, and supplier-related quality remediation charges. A Hold recommendation is warranted as the market waits for the completion of the divestitures and initial execution under the new leadership team. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$138.00 Mean target$152.55 High · most bullish analyst$169.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Regulatory or operational delays push the closing of the divestitures into 2027, prolonging the period of elevated transition costs and strategic uncertainty. Core franchises face continued pricing pressure, and integration issues with BIOTRONIK dilute margins further. Stranded costs remain sticky, and the new CEO faces execution hurdles, leading to a downward revision of long-term growth targets. Base CaseCentral scenario The company successfully closes its planned divestitures in the second half of 2026, utilizing the proceeds to execute the $1 billion share buyback and $800 million debt paydown. Organic constant currency revenue growth tracks within the guided 4.5% to 5.5% range, and adjusted EPS meets the midpoint of the $6.25 to $6.55 guidance. Margins begin to recover as stranded costs are addressed and the higher-margin core portfolio takes center stage. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |